0830 GMT - Novo Nordisk's sales guidance is materially ahead of expectations, Intron Health's Naresh Chouhan writes. The company expects sales to grow 16%-24% this year with EBIT growing 19%-27%. Fourth-quarter EBIT beat expectations by 9% as the gross margin beat by 140 basis points and the EBIT margin beat by 170 basis points. "Given recent concerns on growth, we expect the shares to be up strongly this morning given the sales guidance is materially higher than consensus was expecting and Wegovy was in-line," Chouhan says. Shares trade 4.3% higher at 617.90 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 03:30 ET (08:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.